Corrigendum:

Effects of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one on serum levels of antioxidant enzymes in hyperlipidemic rats

https://doi.org/10.19106/JMedSci005502202301

In the original article, both of authors and institution were incorrect. The correct version is given below:

Prasetyastuti*, Noviyanty Indjar Gama, Rahmah Dara Ayunda

1Department of Biochemistry, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta; 2Faculty of Pharmacy, Universitas Mulawarman, Samarinda, 3Department of Biochemistry Faculty of Medicine Universitas Mataram Indonesia

Errors in Abstract:
Dose 10,30 and 90 mg/200g BW were higher than control group that was not intervened.
Correct version
Dose 10,30 and 90 mg/200g BW were higher than the hyperlipidemic group

Errors in Abstract:
10,30 dan 90 mg/200g BW lebih tinggi dibanding kelompok kontrol yang tidak di intervensi
Correct version
10,30 dan 90 mg/200g BW lebih tinggi dibanding kelompok hyperlipidemia

Errors in Results (Serum level of SOD)
The results showed that the cholesterol-induced rats (HL) had lower serum SOD levels than the normal group (N) (FIGURE 1). Serum SOD levels in hyperlipidemic rats that were intervened with 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose 10,30 and 90 mg/200g BW were higher than HL group that was not intervened.
Correct version
The results showed that the cholesterol-induced rats (HL) had lower serum SOD levels than the normal group (N) (FIGURE 1). Serum SOD levels in hyperlipidemic rats that were intervened with 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose 10,30 and 90 mg/200g BW were higher than the hyperlipidemic group.
**Error in Figure 1**

![Figure 1](image.png)

FIGURE 1. Serum SOD levels (%) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova test, Notation*: p <0.05 vs P; #: p <0.05 vs HL.

There was incorrect in Figure 1. Treatment group HL: 23.15+/- 4.88; P: 63.59+/- 3.22; F10: 31.64+/- 3.53; F30: 54.41+/- 3.94; F90: 58.91+/-4.88 it should HL: 39.45+/-4.88; P: 72.14+/-3.22; F10: 49.25+/-3.53; F30: 56.47+/-3.94; F90: 67.91+/-4.88

**Figure 1 correction**

![Figure 1_correction](image.png)

FIGURE 1. Serum SOD levels (%) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova test, Notation*: p <0.05 vs P; #: p <0.05 vs HL.
There was incorrect in Figure 2

FIGURE 2. Serum CAT levels (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova, p <0.05. Notation *: p <0.05 vs P; #: p <0.05 vs HL.

There was incorrect in Figure 2. Treatment group P: 5.12 +/- 1.8 It should P: 5.12 +/- 0.18

Error in Figure 2

FIGURE 2. Serum CAT levels (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova, p <0.05. Notation *: p <0.05 vs P; #: p <0.05 vs HL.
There was incorrect in Figure 3

There was incorrect Treatment group N: 79.85±1.45 It should Treatment group N: 74.47±1.45

Figure 3 correction

The authors would like to apologize for any confusion caused.